Recent Publications and Grants

Engaged in diverse basic, translational and clinical research, our faculty routinely publish in prestigious journals and successfully compete for major grants from national funders.

Recent Publications

Information not available

We apologize: recent faculty publications are not available at the moment.

Research Grants

  • A phase 3 double-blind study to evaluate the efficacy and safety of oral ozanimod compared to oral fingolimod in children and adolescents with relapsing-remitting multiple sclerosis. Michael Dwyer, III (Co-Investigator). Bristol Myers Squibb. $1,649,376. 6/1/2023-12/1/2032.
  • CTSA State University of New York at Buffalo. Zackary Falls (Contributor). National Center for Advancing Translational Sciences (NCATS). $29,204,726. 1/1/2025-12/1/2031.
  • Clinical and Translational Science Award. Core Operations Special Populations. Ralph Benedict (Co-Investigator). NIH. $29,204,726. 1/1/2025-12/1/2031.
  • Clinical and Translational Science Award. University at Buffalo Clinical and Translational Science Institute. Timothy Murphy (Principal Investigator). NIH. 1/1/2025-12/1/2031.
  • Molecular Physiology of NMDA Receptors. Gabriela Popescu (Principal Investigator). NINDS. $4,200,000. 5/1/2023-4/1/2031.
  • NIH NCATS ASPIRE Design Award. Ram Samudrala (Principal Investigator). NIH. $100,000. 9/1/2019-1/1/2030.
  • NIH NCATS ASPIRE Reduction-to-Practice Award. Ram Samudrala (Co-Principal Investigator). NCATS. $1,220,000. 8/1/2021-1/1/2030.
  • Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy. Pablo Paez (Co-Investigator). National Institute of Neurological Disorders and Stroke (NINDS). $1,950,000. 2/1/2025-1/1/2030.
  • Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy. Daesung Shin (Principal Investigator). NIH. $2,013,407. 12/1/2024-12/1/2029.
  • Overdose Data to Action in States (OD2A): Bio surveillance. Brian Clemency (Principal Investigator). Centers for Disease Control and Prevention (Subaward from NYS Department of Health/Health Research Inc.). $250,000. 9/1/2024-8/1/2029.
  • Rhythm Evaluation for AntiCoagulaTion for Atrial Fibrillation (REACT AF). Anne Curtis (Co-Investigator). NIH. $66,278. 8/1/2023-7/1/2029.
  • Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL. Lisa Niswander (Principal Investigator). NIH/NCI. 7/1/2024-7/1/2029.
  • Characterizing the role of Elevated dNTP pools in sensitizing the replisome. Jennifer Surtees (Principal Investigator). NIGMS. $2,448,745. 9/1/2024-6/1/2029.
  • NIMHD Center of Excellence in Investigator Development and Community Engagement. Timothy Murphy (Principal Investigator). NIH. $3,600,000. 7/1/2024-6/1/2029.
  • Molecular Mechanisms of Severe Diabetic Retinopathy. Joshua Jianxin Wang (Co-Investigator). NIH/NEI. $2,374,855. 2/1/2020-5/1/2029.